Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Effects of approval delays on public health should be measured by FDA -- Rep. McIntosh.

This article was originally published in The Gray Sheet

Executive Summary

EFFECT OF FDA APPROVAL DELAYS ON PUBLIC HEALTH SHOULD BE MEASURED by the agency, Rep. David McIntosh (R-Ind.) said Sept. 14 at a joint hearing of the House Government Reform Committee's Human Resources and National Economic Growth Subcommittees. McIntosh, who chairs the latter subcommittee, suggested that FDA should develop a mechanism to calculate "how many lives were lost and what the [other] downsides were to" delays in the approval process. Eventually, he added, the agency would have a "body of information" that could be used in an effort to balance the need between keeping unsafe devices off the market and speeding devices with a significant potential to save lives onto the market.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT004700

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel